Search results for "PROGNOSIS"

showing 10 items of 2052 documents

Cardiovascular Events During and After Bronchiectasis Exacerbations and Long-term Mortality.

2022

ABSTRACT Background Population-based and retrospective studies have shown that risk for cardiovascular events such as arrythmias, ischemic episodes or heart failure, increase during and after bronchiectasis exacerbations. Research Question What are the risk factors for cardiovascular events (CVE) during and after bronchiectasis exacerbations and its impact on mortality? Study Design and Methods This was a post-hoc retrospective analysis of a prospective observational study of 250 patients with bronchiectasis at two tertiary care hospitals. Only the first exacerbation was considered for each patient, collecting demographic, comorbidity, and severity data. The main outcomes were the appearanc…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCOPDeducation.field_of_studyBronchiectasisExacerbationbusiness.industryPopulationHazard ratioRetrospective cohort studyCritical Care and Intensive Care Medicinemedicine.diseasePrognosisComorbidityBronchiectasisCommunity-acquired pneumoniaCardiovascular DiseasesRisk FactorsInternal medicinemedicineHumansCardiology and Cardiovascular MedicinebusinesseducationRetrospective StudiesChest
researchProduct

Obstructive sleep apnea and comorbidities: a dangerous liaison

2018

Obstructive sleep apnea (OSA) is a highly prevalent disease, and is traditionally associated with increased cardiovascular risk. The role of comorbidities in OSA patients has emerged recently, and new conditions significantly associated with OSA are increasingly reported. A high comorbidity burden worsens prognosis, but some data suggest that CPAP might be protective especially in patients with comorbidities. Aim of this narrative review is to provide an update on recent studies, with special attention to cardiovascular and cerebrovascular comorbidities, the metabolic syndrome and type 2 diabetes, asthma, COPD and cancer. Better phenotypic characterization of OSA patients, including comorbi…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyDiseaseType 2 diabetesReviewSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciences0302 clinical medicinecardiovascular diseaseDiabetes mellitusmedicinecancerCOPDMortalityIntensive care medicineAsthmalcsh:RC705-779COPDdiabetesbusiness.industrylcsh:Diseases of the respiratory systemasthmamedicine.diseaseComorbiditynervous system diseasesrespiratory tract diseasesObstructive sleep apnea030228 respiratory systemdiabeteprognosisMetabolic syndromebusiness030217 neurology & neurosurgeryMultidisciplinary Respiratory Medicine
researchProduct

German Thoracic Research Scholarship 1996: lung volume reduction for endstage pulmonary emphysema at the Washington University of St. Louis.

1998

The Thoracic Research Scholarship 1996 of the German Society for Thoracic and Cardiovascular Surgery enabled me to visit Barnes Hospital at the Washington University of St. Louis, USA, from May to July 1996. At that center Prof. J. D. Cooper has established lung-volume reduction surgery as a successful surgical treatment for patients with endstage pulmonary emphysema. The operation is performed using left-sided double-lumen intubation. After opening of the chest and pleura and starting single-lung ventilation the less diseased parts of the second lung collapse due to absorption atelectasis whereas the more diseased portion of the lung stays hyperinflated. Linear staplers buttressed with bov…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyUniversitiesmedicine.medical_treatmentPulmonary emphysemaAtelectasisGermanyPreoperative CaremedicineIntubationAnimalsHumansLung volumesLung Diseases ObstructiveFellowships and ScholarshipsPneumonectomySocieties MedicalLungMissouribusiness.industryPerioperativerespiratory systemLength of Staymedicine.diseasePrognosisrespiratory tract diseasesSurgerySt louismedicine.anatomical_structureTreatment OutcomePulmonary EmphysemaBreathingSurgeryCattleCardiology and Cardiovascular MedicinebusinessThe Thoracic and cardiovascular surgeon
researchProduct

Systemic Thrombolytic Therapy for Acute Pulmonary Embolism: Who Is a Candidate?

2017

Pulmonary embolism (PE) is a major cause of both acute and long-term morbidity for a large number of patients worldwide, and massive PE is frequently fatal. Right ventricular (RV) dysfunction is a key determinant of prognosis in the acute phase of PE. Patients with clinically overt RV failure, that is, with cardiogenic shock or persistent hypotension at presentation (acute high-risk PE), are clearly in need of immediate reperfusion treatment with systemic thrombolysis or, alternatively, surgical or catheter-directed techniques. On the other hand, within the large group of patients presenting without hemodynamic instability, the bleeding risk of full-dose intravenous thrombolytic treatment h…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyVentricular Dysfunction Rightmedicine.medical_treatmentHemodynamicsSalvage therapy030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicineFibrinolysismedicineHumansThrombolytic TherapyDecompensation030212 general & internal medicineWatchful WaitingIntensive care medicineSalvage Therapybusiness.industryCardiogenic shockAnticoagulantsThrombolysisPrognosismedicine.diseasePulmonary embolismAcute DiseaseCardiologyPulmonary EmbolismbusinessWatchful waitingSeminars in Respiratory and Critical Care Medicine
researchProduct

Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 …

2021

Background The use of Renin-Angiotensin system inhibitors (RASi) in patients with coronavirus disease 2019 (COVID-19) has been questioned because both share a target receptor site. Methods HOPE-COVID-19 (NCT04334291) is an international investigator-initiated registry. Patients are eligible when discharged after an in-hospital stay with COVID-19, dead or alive. Here, we analyze the impact of previous and continued in-hospital treatment with RASi in all-cause mortality and the development of in-stay complications. Results We included 6503 patients, over 18 years, from Spain and Italy with data on their RASi status. Of those, 36.8% were receiving any RASi before admission. RASi patients were …

QA75Malemedicine.medical_specialtyHeart diseaseInfecciones por coronavirusmedicine.medical_treatmentInhibidores enzimáticosPopulationClinical InvestigationsEnfermedad transmisibleAngiotensin-Converting Enzyme InhibitorsSistema renina-angiotensinaComorbidity030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicineRisk FactorsOutcome Assessment Health CareSeverity of illnessmedicineHumansRegistries030212 general & internal medicineMedical prescriptioneducationHeart FailureMechanical ventilationeducation.field_of_studySARS-CoV-2business.industryCOVID-19Middle AgedPrognosismedicine.diseaseR1Respiration ArtificialComorbidityHospitalizationItalySpainHeart failureEmergency medicineFemaleObservational studyCardiology and Cardiovascular MedicinebusinessAmerican Heart Journal
researchProduct

Potential Biomarkers Associated with Multiple Sclerosis Pathology

2021

Multiple sclerosis (MS) is a complex disease of the central nervous system (CNS) that involves an intricate and aberrant interaction of immune cells leading to inflammation, demyelination, and neurodegeneration. Due to the heterogeneity of clinical subtypes, their diagnosis becomes challenging and the best treatment cannot be easily provided to patients. Biomarkers have been used to simplify the diagnosis and prognosis of MS, as well as to evaluate the results of clinical treatments. In recent years, research on biomarkers has advanced rapidly due to their ability to be easily and promptly measured, their specificity, and their reproducibility. Biomarkers are classified into several categor…

QH301-705.5diagnosticInflammationReviewBioinformaticsmultiple sclerosisCatalysisInorganic ChemistryBlood serummedicineHumanspredictivePhysical and Theoretical ChemistryRemyelinationbiomarkers diagnostic multiple sclerosis predictive prognosis treatment response monitoringBiology (General)Molecular BiologyPathologicalQD1-999SpectroscopyInflammationbusiness.industryMultiple sclerosisOrganic ChemistryNeurodegenerationReproducibility of ResultsbiomarkersGeneral Medicinemedicine.diseaseComputer Science ApplicationsChemistrymedicine.anatomical_structureGliosisDisease ProgressionBiomarker (medicine)prognosismedicine.symptombusinesstreatment response monitoringInternational Journal of Molecular Sciences
researchProduct

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib

2020

Background and aims The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods This multicentric study included a training cohort of 194 HCC patients and three external validation cohorts of 129, 76 and 265 HCC patients treated with Sorafenib, respectively. The PNI was calculated as follows: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm3). Univariate and multivariate analyses were performed to investigate the association between the covariates and the overall survival (OS). Results A PNI cut-off value of 31.3 was established using the ROC an…

RNA virusesMaleEtiologyCancer TreatmentHepacivirusKaplan-Meier EstimateBiochemistryCohort StudiesWhite Blood CellsMathematical and Statistical TechniquesRetrospective StudieAnimal CellsAdult; Aged; Aged 80 and over; Antineoplastic Agents; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies; Serum Albumin; Sorafenib; Nutrition AssessmentMedicine and Health Sciences80 and overLymphocytesPathology and laboratory medicineAged 80 and overHepatitis C virusLiver DiseasesStatisticsQLiver NeoplasmsRMedical microbiologyMiddle AgedSorafenibPrognosisOncologyItalyLiver NeoplasmPhysical SciencesVirusesMedicineFemalePathogensCellular TypesHumanResearch ArticleAdultHepatitis B virusCarcinoma HepatocellularImmune CellsScienceImmunologyAntineoplastic AgentsGastroenterology and HepatologySerum Albumin ...Research and Analysis MethodsCarcinomasMicrobiologyAlbuminsGastrointestinal TumorsHumansLymphocyte CountStatistical MethodsSerum AlbuminAgedRetrospective StudiesBlood CellsAdult Aged 80 and over Antineoplastic Agents Carcinoma Hepatocellular Cohort Studies Female Humans Italy Kaplan-Meier Estimate Liver Neoplasms Lymphocyte Count Male Middle Aged Prognosis Retrospective Studies Serum Albumin Sorafenib Nutrition AssessmentBiology and life sciencesFlavivirusesCarcinomaViral pathogensOrganismsCancers and NeoplasmsProteinsHepatocellularHepatocellular CarcinomaCell Biologyprognostic nutritional index (PNI) hepatocellular carcinoma (HCC) sorafenib. survival mRECISTHepatitis virusesMicrobial pathogensNutrition AssessmentMultivariate AnalysisCohort StudieMathematics
researchProduct

Evolution of patients’ socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infecte…

2018

International audience; BACKGROUND:Direct-acting antivirals (DAA) have dramatically increased HCV cure rates with minimal toxicity in HIV-HCV co-infected patients. This study aimed to compare the socio-behavioral characteristics of patients initiating pegylated-interferon (PEG-IFN)-based HCV treatment with those of patients initiating DAA-based treatment.METHODS:ANRS CO13 HEPAVIH is a national multicenter prospective cohort started in 2005, which enrolled 1,859 HIV-HCV co-infected patients followed up in French hospital outpatient units. Both clinical/biological and socio-behavioral data were collected during follow-up. We selected patients with socio-behavioral data available before HCV tr…

RNA virusesMaleHealth BehaviorSocial Scienceslcsh:MedicineHIV InfectionsHepacivirusGeographical locationsChronic Liver Disease0302 clinical medicineRisk FactorsPrevalencePsychologyAlcohol consumptionProspective Studies030212 general & internal medicineYoung adultProspective cohort studylcsh:SciencePathology and laboratory medicinemedia_commonChronic hepatitisDrug injectionClinical Trials as TopicMultidisciplinarybiologyPharmaceuticsCoinfectionHepatitis C virusLiver Diseasesvirus diseasesMedical microbiologyMiddle AgedPrognosisHepatitis CAddicts3. Good healthEuropeBehavioral PharmacologyDrug usersVirusesCohortFemale030211 gastroenterology & hepatologyDrug therapyFrancePathogensResearch ArticleAdultDrugmedicine.medical_specialtySubstance-Related Disordersmedia_common.quotation_subjectLiver fibrosisAddictionContext (language use)Gastroenterology and HepatologyMicrobiologyAntiviral AgentsYoung Adult03 medical and health sciencesPharmacotherapyRecreational Drug UseInternal medicinemedicineHumansEuropean UnionNutritionAgedCannabisMedicine and health sciencesPharmacologyBiology and life sciencesFlavivirusesbusiness.industrylcsh:ROrganismsViral pathogensHIVbiology.organism_classificationHepatitis virusesdigestive system diseasesMicrobial pathogensDiet[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologielcsh:Q[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCannabisPeople and placesbusiness
researchProduct

THE IMPACT OF NUMBER OF LYMPH NODE REMOVED IN THE DETECTION OF LYMPHNODE METASTASIS: A SENSITIVITY CURVE ANALYSIS.

2014

Scopo del lavoro To assess the correct number of lymph nodes (LNs) to removed at Radical Cystectomy (RC) to ensure an accurate lymph nodes metastasis (LNM) staging. Materiali e metodi Between 1995 and 2012, 1016 RC for bladder cancer (BCa) were completed at a single tertiary care institution. Demographical, clinical and pathological variables were recorded for each patient. The relationship between the number of removed LNs and the probability to find a LNI at definitive pathology examination was assessed by receiver operating characteristic (ROC) analyses. The ROC curve coordinates were used to graph the probability of finding LNI according to the number of LNs removed and examined with a …

Radical cystectomy lymphnode metastasis. prognosis bladder cancerSettore MED/24 - Urologia
researchProduct

Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?

2019

Introduction: Radium-223 (223Ra) improves symptoms and survival in patients with bone metastatic castration-resistant prostate cancer (mCRPC). Study aim: To evaluate the impact of a previous radical prostatectomy (RP) on the outcome of 223Ra therapy in mCRPC patients. The primary prostate tumor left untreated could progress during 223Ra treatment. Materials and methods: mCRPC symptomatic patients treated with 223Ra were enrolled. Luteinizing Hormone-Releasing Hormone analogue was maintained. No other anticancer therapy was given. 223Ra was administered i.v. at the dose of 55 kBq/kg every 4 weeks for 6 cycles. Patients were stratified according to previous RP or not. Hematological toxicity w…

Radium-223Malemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyUrologyAntineoplastic AgentsBone NeoplasmsSettore MED/24 - UrologiaPrimary tumor03 medical and health sciencesProstate cancer0302 clinical medicineProstateRadium-222medicineHumansAgedProstatectomyRadiotherapybusiness.industryProstatectomyProstateChemoradiotherapy Adjuvantmedicine.diseasePrognosisRadical prostatectomyPrimary tumorSurvival AnalysisRadiation therapyProstatic Neoplasms Castration-Resistantmedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisConcomitantDisease ProgressionCastration resistant prostate cancerNeoplasm GradingRadiopharmaceuticalsbusinessmedicine.drugHormoneFollow-Up StudiesRadiumUrologic oncology
researchProduct